{
    "ticker": "ZYME",
    "name": "Zymeworks Inc.",
    "description": "Zymeworks Inc. is a biotechnology company focused on the development of multifunctional therapeutics for the treatment of cancer and other serious diseases. Established in 2003 and headquartered in Vancouver, Canada, Zymeworks leverages its innovative Zymeworks platform, which combines protein engineering and drug development technologies to create optimized therapeutic candidates. The company\u2019s lead product candidates include ZW25, an engineered bispecific antibody designed for the treatment of HER2-positive cancers, and ZW49, a next-generation drug conjugate. Zymeworks is dedicated to advancing its pipeline of therapeutics through collaborative partnerships with leading pharmaceutical companies, and it aims to deliver breakthrough therapies that improve patient outcomes. The company's mission is to transform the lives of patients by harnessing the power of biotechnology to develop novel and effective drug candidates. With a strong emphasis on research and development, Zymeworks is committed to innovation and excellence in the biopharmaceutical industry.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Vancouver, British Columbia, Canada",
    "founded": "2003",
    "website": "https://www.zymeworks.com",
    "ceo": "Ali Tehrani",
    "social_media": {
        "twitter": "https://twitter.com/Zymeworks",
        "linkedin": "https://www.linkedin.com/company/zymeworks/"
    },
    "investor_relations": "https://investors.zymeworks.com",
    "key_executives": [
        {
            "name": "Ali Tehrani",
            "position": "CEO"
        },
        {
            "name": "Kathy J. D. R. McCoy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ZW25",
                "ZW49"
            ]
        }
    ],
    "seo": {
        "meta_title": "Zymeworks Inc. | Biotechnology and Therapeutics Development",
        "meta_description": "Explore Zymeworks Inc., a leading biotechnology company focused on developing multifunctional therapeutics for cancer and other diseases. Discover our innovative platform and pipeline.",
        "keywords": [
            "Zymeworks",
            "Biotechnology",
            "Cancer Treatment",
            "Therapeutics",
            "ZW25",
            "ZW49"
        ]
    },
    "faq": [
        {
            "question": "What does Zymeworks specialize in?",
            "answer": "Zymeworks specializes in developing multifunctional therapeutics for cancer and other serious diseases."
        },
        {
            "question": "Who is the CEO of Zymeworks?",
            "answer": "Ali Tehrani is the CEO of Zymeworks Inc."
        },
        {
            "question": "Where is Zymeworks headquartered?",
            "answer": "Zymeworks is headquartered in Vancouver, British Columbia, Canada."
        },
        {
            "question": "What are Zymeworks' main products?",
            "answer": "Zymeworks' main products include ZW25 and ZW49, which are designed for cancer treatment."
        },
        {
            "question": "When was Zymeworks founded?",
            "answer": "Zymeworks was founded in 2003."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "BMY",
        "SNY"
    ],
    "related_stocks": [
        "NVAX",
        "BMY",
        "AMGN",
        "TGTX"
    ]
}